The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee
Open accessAbstract
Introduction: 5-Loxin ® is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme. A 90-day, double-blind, randomized, placebo-controlled study was conducted to evaluate the efficacy and safety of 5-Loxin ® in the treatment of osteoarthritis (OA) of the knee. Methods: Seventy-five OA patients were included in the study. The patients received either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin ® daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne's Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients. Measurement of a battery of biochemical parameters in serum and haematological parameters, and urine analysis were performed to evaluate the safety of 5-Loxin ® in OA patients. Results: Seventy patients completed the study. At the end of the study, both doses of 5-Loxin ® conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin ® as early as 7 days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3. In comparison with placebo, the safety parameters were almost unchanged in the treatment groups. Conclusion: 5-Loxin ® reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin ® may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients. Trail Registration: (Clinical trial registration number: ISRCTN05212803.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoarthritis: New Insights. Part 1: The Disease and Its Risk Factors
Felson, D. T., Lawrence, R. C., Dieppe, P. A., Hirsch, R., Helmick, C. G., Jordan, J. M., Kington, R. S., Lane, N. E., Nevitt, M. C., Zhang, Y., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-8-200010170-00016 · Cited by 2,519
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update
(2000) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200009)43:9<1905::aid-anr1>3.0.co;2-p · Cited by 1,875
Zhang, W., Doherty, M., Leeb, B. F., Alekseeva, L., Arden, N. K., Bijlsma, J. W., Dinçer, F., Dziedzic, K., Häuselmann, H. J., Herrero-Beaumont, G., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062091 · Cited by 1,338
Felson, D. T., & McAlindon, T. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-1-200201010-00019 · Cited by 1,122
Chapman, C. R., Casey, K. L., Dubner, R., Foley, K. M., Gracely, R. H., & Reading, A. E. (1985) · Pain · doi:10.1016/0304-3959(85)90145-9 · Cited by 1,087
Felson, D. T. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp051726 · Cited by 986
Guidelines for the medical management of osteoarthritis
Hochberg, M. C., Altman, R. D., Brandt, K. D., Clark, B. M., Dieppe, P. A., Griffin, M. R., Moskowitz, R. W., & Schnitzer, T. J. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780381103 · Cited by 968
The Importance of Placebo Effects in Pain Treatment and Research
Turner, J. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510440069036 · Cited by 874
McAlindon, T. E., LaValley, M. P., Gulin, J. P., & Felson, D. T. (2000) · JAMA · doi:10.1001/jama.283.11.1469 · Cited by 849
Lequesne, M. G., Mery, C., Samson, M., & Gerard, P. (1987) · Scandinavian Journal of Rheumatology · doi:10.3109/03009748709102182 · Cited by 786
Cited by
Boswellia serrata: An Overall Assessment of In Vitro, Preclinical, Pharmacokinetic and Clinical Data
Abdel-Tawab, M., Werz, O., & Schubert-Zsilavecz, M. (2011) · Clinical Pharmacokinetics · doi:10.2165/11586800-000000000-00000 · Cited by 311
Haroyan, A., Mukuchyan, V., Mkrtchyan, N., Minasyan, N., Gasparyan, S., Sargsyan, A., Narimanyan, M., & Hovhannisyan, A. (2018) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-2062-z · Cited by 232
Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis
Bannuru, R. R., Osani, M. C., Al-Eid, F., & Wang, C. (2018) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2018.03.001 · Cited by 110
Metadata
- Authors
- Sengupta, K., Alluri, K. V., Satish, A. R., Mishra, S., Golakoti, T., Sarma, K. V., Dey, D., & Raychaudhuri, S. P.
- Venue
- Arthritis Research & Therapy
- Published
- 2008-07-30
- Volume
- 10
- Issue
- 4
- Pages
- R85-R85
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W2059544487
- Cited by
- 254
- References
- 32
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee. https://app.cochat.ai/papers/10.1186/ar2461
- The paper
- Sengupta, K., Alluri, K. V., Satish, A. R., Mishra, S., Golakoti, T., Sarma, K. V., Dey, D., & Raychaudhuri, S. P. (2008). A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee. Arthritis Research & Therapy. https://doi.org/10.1186/ar2461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.